28
Participants
Start Date
April 19, 2018
Primary Completion Date
July 31, 2020
Study Completion Date
July 31, 2020
MASCT-I
The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
PD1 antibody
"Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study."
RECRUITING
Beijing Cancer Hospital, Beijing
Lead Sponsor
Peking University Cancer Hospital & Institute
OTHER
HRYZ Biotech Co.
INDUSTRY